Grand Rapids, MI – June 11, 2024 – NxGen MDx, a leading provider of advanced genetic testing solutions, has announced the launch of a new Fetal RhD option for their Non-Invasive Prenatal Screen (NIPS). This addition allows expectant parents and healthcare providers to determine the RhD status of the fetus as early as 10 weeks into the pregnancy. This crucial information can significantly improve prenatal care and outcomes, especially in light of the global RhoGAM shortage.
Over a decade ago, NxGen MDx’s founder, Alan Mack, launched the original fetal RhD test. At that time, RhoGAM was readily available, and the test did not achieve widespread use. Today, with the global shortage of RhoGAM, NxGen MDx’s advanced fetal RhD test offers a timely solution, helping to reduce the dependency on RhoGAM by identifying Rh-negative women who truly need the treatment.
The RhD factor, a protein found on the surface of red blood cells, is crucial in pregnancy management. Rh incompatibility, where an Rh-negative mother carries an Rh-positive fetus, can lead to serious complications like hemolytic disease of the newborn (HDN). Early detection of the fetus's RhD status allows
for timely interventions, reducing risks and promoting better health for both mother and child. In the midst of the current RhoGAM shortage, early Rh status determination is essential for planning and triaging care
and possible RhoGAM treatment.
The Fetal RhD option is integrated into NxGen MDx's comprehensive NIPS, which analyzes cell-free fetal DNA in the mother's blood. This non-invasive method eliminates risks associated with traditional procedures like amniocentesis, making it safer for both mother and fetus. With a No-Call Rate of 0.3%, the
test delivers highly accurate and reliable results.
In addition to Fetal RhD status, NxGen MDx's NIPS screens for common chromosomal abnormalities such as Down Syndrome, trisomy 18, and trisomy 13, with expanded aneuploidy and microdeletions options available.
"We are committed to advancing prenatal screening technology and improving maternal-fetal health outcomes," said Alan Mack, CEO of NxGen MDx. “Our new Fetal RhD option is a valuable addition, especially in light of the global RhoGAM shortage. We are proud to offer this innovative solution to expectant families and healthcare providers.”
NxGen MDx continues to lead the way in genetic testing, providing state-of-the-art solutions that address critical needs in prenatal care. With the launch of the Fetal RhD option, we reaffirm our dedication to enhancing healthcare outcomes for our patients.
NxGen MDx is a leading provider of advanced genetic testing solutions, committed to delivering accurate and actionable information to healthcare providers and patients. Founded with a mission to improve health outcomes through innovative testing technologies, NxGen MDx offers a wide range of services including carrier screening, prenatal screening, hereditary cancer testing, and pathogen testing. Utilizing state-of-the-art technology and a team of laboratory and clinical experts, NxGen MDx ensures the highest standards of accuracy, reliability, and patient care. For more information, visit www.nxgenmdx.com.